Answers are grounded in this paper and cite their sources.
Dear Editor, The anti‐programmed death‐1 (PD‐1) antibody pembrolizumab, routinely used for treatment of metastatic melanoma or nonsmall cell lung cancer, was recently shown to have clinically meaningful activity in metastatic Merkel cell carcinoma (MCC).1 Several cases of bullous pemphigoid (BP) induced by PD‐1 antibodies in melanoma have been reported so far. Here we report a case of oral mucous membrane pemphigoid (MMP) – a previously unknown, severe immune‐related adverse event (irAE) occurring during pembrolizumab therapy. A 62‐year‐old male patient on first‐line treatment with pembrolizumab (2 mg kg−1, every 3 weeks) for unresectable, lymphonodal metastatic MCC developed oral erosions and aphthous ulcers 13 weeks after initiation of therapy. Clinical examination showed erosions and blisters limited to the oral mucous membranes, especially the tongue and buccal mucosa (Fig. 1a, b). Being mentally impaired due to trisomy 21, the patient could not express his painful oral symptoms other than by refusing meals, with consecutive weight loss. There were no clinical signs of involvement of the nose or eyes. Clinical findings and immunofluorescence. Inflammation and erosions affecting the buccal mucosa (a) and the tongue (b). (c) Direct immunofluorescence showing linear C3 deposition along the dermoepidermal junction in a biopsy taken perilesionally. (d) Indirect immunofluorescence revealing circulating IgG autoantibodies binding to the roof of the artificial blister of salt‐split skin (diluted 1 : 10, original magnification ×16). Direct immunofluorescence microscopy of perilesional skin revealed deposition of C3 antibodies along the dermoepidermal junction (Fig. 1c). Indirect immunofluorescence of salt‐split skin showed circulating IgG (titre 1 : 320) and IgA autoantibodies (titre 1 : 40) binding to the roof of the artificial blister (Fig. 1d). Enzyme‐linked immunosorbent assay (ELISA) indicated the presence of anti‐BP180 NC16A (IgG) antibodies (23·6 U mL−1; upper limit of normal 9 U mL−1). Immunoblots were performed to detect circulating IgG antibodies binding to the soluble 120‐kDa ectodomain of BP180 (LAD‐1) and IgG and IgA antibodies against the C‐terminal segment 4575 of BP180. Taken together, these findings were diagnostic of MMP. The patient was treated by oral anti‐inflammatory therapy with doxycycline (100 mg twice daily) and a topical steroid (mometasone furoate 0·1%). After 6 weeks the erosions had healed, and accordingly the titre of anti‐BP180 NC16A (IgG) antibodies decreased to 12·7 U mL−1. Pembrolizumab was discontinued at the time of onset of MMP. In terms of treatment response, computed tomography scans had shown a partial response (according to the RECIST 1.1 criteria) after three cycles of therapy. The disease is being monitored by clinical examination and radiological imaging. As of writing, partial response has been maintained at 24 weeks after terminating therapy. Autoimmune blistering diseases (AIBDs) are mediated by autoantibodies against parts of the basal membrane zone or intraepidermal antigens. However, they can also be triggered by autoreactive T cells. Regulatory T cells and the PD‐1–PD ligand pathway are critical in terminating immune responses. Elimination of either can result in breakdown of tolerance and emergence of autoimmunity. Checkpoint‐inhibiting therapies such as pembrolizumab are known to produce cutaneous irAEs. These comprise lichenoid dermatitis, sarcoid‐like lesions and vitiligo.2 To the best of our knowledge, MMP as an irAE has not been described yet, whereas several cases of BP, another AIBD, induced by PD‐1 antibodies in melanoma have been reported previously.2,3,4 The mechanisms underlying such cutaneous reactions are not yet fully clarified, but it is assumed that the antagonism of PD‐1 leads to a loss of T‐cell homeostasis within the skin and mucous membranes, inducing autoinflammatory and cytotoxic reactions. Histopathological examinations revealed an accumulation of CD8+ cytotoxic cells.5 MMP may have developed independently of therapy. However, the incidence in Germany is very low (0·87–2 per 1 million).6 Correct diagnosis is often delayed due to the rare incidence and variable clinical symptoms. All mucous membranes can be affected, but especially the mouth (85%).6 Typical symptoms are painful erythema, blistering and erosions on the gingiva and palate, less frequently on the lips, tongue or mucous membranes of the cheeks.6 Differential diagnoses encompass pemphigus vulgaris, BP, Behçet disease and lichen planus mucosae. Erythema multiforme and infectious diseases such as herpetic gingivostomatitis and neutropenia also have to be considered in patients with oral inflammation and ulceration. Blistering is caused by autoantibodies against adhesion molecules of the dermoepidermal junction. At least 10 different target antigens have been identified so far.6 Diagnosis is based on clinical and immunological criteria. The gold standard is a perilesional biopsy for direct immunofluorescence. Via indirect immunofluorescence, ELISA and Western blot, circulating autoantibodies can be detected and the relevant autoantigen(s) identified. MMP limited to the oral membranes is considered a low‐risk disease with a good prognosis and various therapeutic options.6 Here we describe an unusual case of MMP that developed under pembrolizumab therapy in a patient with metastatic MCC, treated successfully with doxycycline and topical steroids. Diseases affecting the oral mucosa are frequent in patients with cancer. As they are known to induce cachexia, malnutrition, reduced quality of life and pain, severe oral irAEs should not be underestimated.
No takes yet. Share an insight, caveat, or question.
Haug et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: